Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Levetiracetam

Klassificering: A

Preparat: Desitrend, Keppra, Kevesy, Levetiracetam 1A Farma, Levetiracetam 2care4, Levetiracetam Accord, Levetiracetam Actavis, Levetiracetam Actavis Group, Levetiracetam Amneal, Levetiracetam Aristo, Levetiracetam Bluefish, Levetiracetam Desitin, Levetiracetam Ebb, Levetiracetam Hospira, Levetiracetam Navamedic, Levetiracetam Orifarm, Levetiracetam Orion, Levetiracetam STADA, Levetiracetam SUN, Levetiracetam Teva, Matever

ATC kod: N03AX14

Substanser: levetiracetam

Sammanfattning

Det saknas kontrollerade studier om skillnader mellan könen avseende effekt av levetiracetam.
 
Kunskapsunderlaget avseende skillnader mellan kvinnor och män är begränsat och motiverar inte olika dosering eller behandling.

Additional information

Pharmacokinetics and dosing

There is no evidence for relevant sex differences in levetiracetam pharmacokinetics [1]. According to clinical studies done by the original manufacturer (12 men, 11 women), levetiracetam Cmax and AUC were 20% higher in women than men. However, clearances adjusted for body weight were comparable [2]. Another study found no significant sex differences in pharmacokinetic parameters of levetiracetam in children aged 2.3-46.2 months [3].

In pregnancy, decreasing concentrations are found already from the first trimester and up to 40-60% in the third trimester (increased renal elimination or enzymatic hydrolysis). The inter-individual variation is large and a fast normalization is seen after delivery [4].  

Effects

No studies with a clinically relevant sex analysis regarding the effects of levetiracetam have been found.

Adverse effects

A clinical trial (30 men, 27 women) found no apparent sexual or endocrine side effects of levetiracetam treatment in men and women (age 18-45 years). Men treated with levetiracetam had lower free testosterone and androstenedione levels than healthy controls, but this was also seen in men treated with either carbamazepine or lamotrigine. This could thus be a difference between persons with and without epilepsy, and not a specific drug effect. Menstrual disturbances were more commonly reported in the epilepsy group than in the control group, but there were no difference in menstrual disturbances between treated women and controls. According to ASEX scores (Arizona Sexual Experience Scale), women using levetiracetam were more satisfied with their sexual lives than healthy controls without epilepsy while no differences were found in men.  The etiology of this improvement in women is unclear [5]. A cross-sectional cohort study found no impact of levetiracetam monotherapy for 6 months on serum concentrations of sex-steroid hormones in pre-pubertal children. However, this study had a small sample size (7 boys and 3 girls on levetiracetam). There is reason to assume that levetiracetam monotherapy for 6 months does not result in clinically relevant endocrine side effects in prepubertal children [6].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Något fler män än kvinnor hämtade ut läkemedel innehållande levetiracetam (ATC-kod N03AX14) på recept i Sverige år 2015, totalt 9 910 män och 9 500 kvinnor. Det motsvarar 2,0 respektive 2,0 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70 år och äldre hos båda könen. I åldersgruppen 70 år och äldre var läkemedel innehållande levetiracetam i genomsnitt 1,4 gånger vanligare hos män [7].,, 

Uppdaterat: 2019-02-26

Litteratursökningsdatum: 2013-03-06

Referenser

  1. Levetiracetam. Summary of Product Characteristics. European Medicines Agency. [updated 2014-01-08, cited 2016-04-04]. länk
  2. Levetiracetam. DailyMed [www]. US National Library of Medicine. [updated 2011-12-01, cited 2013-03-06]. länk
  3. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405-14. PubMed
  4. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48:1117-22. PubMed
  5. Svalheim S, Taubøll E, Luef G, Lossius A, Rauchenzauner M, Sandvand F et al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav. 2009;16:281-7. PubMed
  6. Rauchenzauner M, Bitsche G, Svalheim S, Tauboll E, Haberlandt E, Wildt L et al. Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children--results from a pilot study. Epilepsy Res. 2010;88:264-8. PubMed
  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-30.] länk

Författare: Linnéa Karlsson Lind, Desirée Loikas

Faktagranskat av: Expertrådet för neurologiska sjukdomar, Ellen Vinge

Godkänt av: Karin Schenck-Gustafsson